Skip to main content

Table 1 Summary of antitumor activity of lenvatinib in seven subcutaneous xenograft models

From: Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage

Tumor cell IC501)(μM) TV2)(mm3) ΔTV (%)3)lenvatinib (mg/kg)
1 3 10 30 100
MDA-MB 4354) (Melanoma) 24.2 180 55.7* 56.9* 40.2* 21.2* 25.7*
MIApaca-II5) (Pancreas) 33.8 250 56.1* 49.9* 30.1* 15.3* 12.5*
H4605) (Lung) 26.3 110 65.4 34.9* 16.3* 16.4* -0.8*
SK-OV-35) (Ovary) 26.4 230 52.3* 39.6* 12.2* 8.3* -15.6*
Colo2055) (Colon) 27.5 320 43.8* 23.1* 12.8* -4.5* -21.3*
A4315) (Epidermoid) 30.8 310 41.7 29.4* 0.0* -7.5* -32.9*
DU1454) (Prostate) 30.8 160 -7.5* -42.2* -65.4* -72.0* -78.6*
  1. 1)In vitro anti-proliferative activity of lenvatinib.
  2. 2)Lenvatinib treatments started at indicated tumor volumes.
  3. 3)ΔT/C of individual mice was determined first, and then an mean value was calculated.
  4. 4)Lenvatinib was orally administered twice daily for 28 days.
  5. 5)Lenvatinib was orally administered twice daily for 14 days.
  6. *p < 0.05 versus vehicle control.